



Published in final edited form as:

*Aliment Pharmacol Ther.* 2013 November ; 38(10): 1267–1277. doi:10.1111/apt.12518.

## Pediatric Gastroenterology Evaluation of Overweight and Obese Children Referred from Primary Care for Suspected Nonalcoholic Fatty Liver Disease

Jeffrey B. Schwimmer, MD<sup>1,2,3</sup>, Kimberly P. Newton, MD<sup>1,2</sup>, Hannah I. Awai, MD<sup>1,2,3</sup>, Lillian J. Choi, MD<sup>1,2</sup>, Mary Abigail Garcia, MD<sup>1,2</sup>, Linda L. Ellis, MD<sup>4,5,6</sup>, Karen Vanderwall, MD<sup>7</sup>, and John Fontanesi, PhD<sup>8,9</sup>

<sup>1</sup>Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of California, San Diego School of Medicine, San Diego, California

<sup>2</sup>Department of Gastroenterology, Rady Children's Hospital San Diego, San Diego, California

<sup>3</sup>Liver Imaging Group, Department of Radiology, University of California, San Diego School of Medicine, San Diego, California

<sup>4</sup>Department of Pathology, Rady Children's Hospital San Diego, San Diego, California

<sup>5</sup>Department of Pathology, University of California, San Diego School of Medicine, La Jolla, California

<sup>6</sup>Department of Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, Hamden, Connecticut

<sup>7</sup>Department of Anesthesiology, Rady Children's Hospital San Diego, San Diego, California

<sup>8</sup>Center for Management Science in Health, Division of General Internal Medicine, Department of Medicine, University of California, San Diego School of Medicine, La Jolla, California

<sup>9</sup>Departments of Family and Preventive Medicine and Pediatrics, University of California, San Diego School of Medicine, La Jolla, California

---

Address correspondence to: Jeffrey B. Schwimmer, M.D., Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Diego, 3020 Children's Way, MC 5030 San Diego, CA 92123, jschwimmer@ucsd.edu, phone: 858-966-8907, fax: 858-560-6798.

### Statement of Interests:

The authors have no conflicts of interest to disclose.

### AUTHOR STATEMENT:

**Guarantor of article:** Jeffrey B. Schwimmer, M.D.

**Specific author contributions:** All authors approved the final version of the article, including the authorship list.

**Jeffrey B. Schwimmer:** Dr. Schwimmer conceptualized and designed the study, acquired data, interpreted data, drafted the manuscript, and approved the final manuscript as submitted.

**Kimberly P. Newton:** Dr. Newton designed the study, acquired data, critically reviewed and revised the manuscript and approved the final manuscript as submitted.

**Hannah I. Awai:** Dr. Awai acquired data, critically reviewed and revised the manuscript and approved the final manuscript as submitted.

**Lillian J. Choi:** Dr. Choi acquired data, critically reviewed and revised the manuscript and approved the final manuscript as submitted.

**Mary Abigail Garcia:** Dr. Garcia acquired data, critically reviewed and revised the manuscript and approved the final manuscript as submitted.

**Linda L. Ellis:** Dr. Ellis acquired data, critically reviewed and revised the manuscript and approved the final manuscript as submitted.

**Karen Vanderwall:** Dr. Vanderwall acquired data, drafted the manuscript, and approved the final manuscript as submitted.

**John Fontanesi:** Dr. Fontanesi contributed to study design, performed statistical analysis, interpreted data, drafted the manuscript, and approved the final manuscript as submitted.

## Abstract

**Background**—Screening overweight and obese children for nonalcoholic fatty liver disease (NAFLD) is recommended by pediatric and endocrinology societies. However, gastroenterology societies have called for more data before making a formal recommendation.

**Aim**—To determine whether the detection of suspected NAFLD in overweight and obese children through screening in primary care and referral to pediatric gastroenterology, resulted in a correct diagnosis of NAFLD.

**Methods**—Information generated in the clinical evaluation of 347 children identified with suspected NAFLD through screening in primary care and referral to pediatric gastroenterology was captured prospectively. Diagnostic outcomes were reported. The diagnostic performance of two times the upper limit of normal for alanine aminotransferase (ALT) was assessed.

**Results**—NAFLD was diagnosed in 55% of children identified by screening and referral. Liver disease other than NAFLD was present in 18% of those referred. Autoimmune hepatitis was the most common alternate diagnosis. Children with NAFLD had significantly ( $p < 0.05$ ) higher screening ALT ( $98 \pm 95$ ) than children with liver disease other than NAFLD ( $86 \pm 74$ ). Advanced fibrosis was present in 11% of children. For the diagnosis of NAFLD, screening ALT two times the clinical upper limit of normal had a sensitivity of 57% and a specificity of 71%.

**Conclusions**—Screening of overweight and obese children in primary care for NAFLD with referral to pediatric gastroenterology has the potential to identify clinically relevant liver pathology. Consensus is needed on how to value the risk and rewards of screening and referral in order to identify children with liver disease in the most appropriate manner.

## INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children.(1) The diagnosis of NAFLD requires that 5% or more hepatocytes have macrovesicular steatosis, and that other liver diseases and/or clinical conditions which may cause steatosis are excluded.(2) Approximately 25% of children with NAFLD have a progressive sub-phenotype known as nonalcoholic steatohepatitis (NASH).(3) Some children with NASH will develop cirrhosis and end-stage liver disease.(4–6) Thus NAFLD is not a singular diagnosis but a clinical-pathological diagnosis that encompasses a broad spectrum of liver disease ranging from isolated steatosis to steatohepatitis, fibrosis, and cirrhosis.(7)

For the years 1993–2003, the prevalence of NAFLD in children age 2–19 years was estimated to be 9.6%.(1) Studies have consistently shown that obesity is one of the most important risk factors for pediatric NAFLD. (1, 8–11) An overweight or obese child with elevated alanine aminotransferase (ALT) is typically considered to have suspected NAFLD. (12) A recent report from the National Health and Nutrition Examination Survey demonstrated that the prevalence of suspected NAFLD in children age 12 to 19 in the United States more than doubled from 1988–1994 to 2007–2010.(13)

In 2005 a report from UC San Francisco and Stanford University noted that general pediatricians were “underscreening” overweight children for NAFLD.(14) Beginning in 2007, major medical societies published guideline statements regarding screening overweight and obese children for NAFLD.(15–17) The positions of these societies are summarized in Table 1. Recommendations for screening have been made by pediatricians, endocrinologists, and pediatric gastroenterologists. The pediatric guidelines state that overweight or obese children 10 years should be screened for NAFLD using serum ALT and aspartate aminotransferase (AST).(18) There is however, some controversy surrounding

screening children for NAFLD. Using published literature through June 2011, the American Gastroenterology Association, American Association for the Study of Liver Diseases, and the American College of Gastroenterology developed a Practice Guideline on the diagnosis and management of NAFLD which was jointly published in *Gastroenterology*(19), *Hepatology*(20), and *American Journal of Gastroenterology*(21) in June 2012. The Practice Guideline states, “Due to a paucity of evidence, a formal recommendation cannot be made with regards to screening for NAFLD in overweight and obese children despite a recent expert committee recommendation for biannual screening for liver disease with liver enzyme measurements in this population.”

In the absence of uniform guidance, physicians must make their own decision whether or not to screen overweight children for NAFLD. Many primary care providers are screening overweight and obese children for NAFLD and many of these children identified as having suspected NAFLD are referred to pediatric gastroenterology for evaluation. The diagnostic outcomes for such children with suspected NAFLD who were referred to pediatric gastroenterology have not been reported. Therefore we sought to address critical gaps in the knowledge base with the following study aims:

1. To describe the population of children who were identified with suspected NAFLD through screening in primary care and referred to pediatric gastroenterology.
2. To determine whether the detection of suspected NAFLD in overweight and obese children through screening in primary care and referral to pediatric gastroenterology, resulted in a correct diagnosis of NAFLD.
3. To determine the frequency of NASH amongst overweight and obese children who were identified with suspected NAFLD through screening in primary care and referred to pediatric gastroenterology.
4. To determine the frequency of advanced fibrosis amongst overweight and obese children who were identified with suspected NAFLD through screening in primary care and referred to pediatric gastroenterology.
5. To determine the diagnostic performance of ALT two times the upper limit of normal (ULN) for the above outcomes amongst overweight and obese children who were identified with suspected NAFLD through screening in primary care and referred to pediatric gastroenterology.

## METHODS

### Study Population

Screening for NAFLD and referral to pediatric gastroenterology was done clinically in primary care prior to participation in the study. Eligibility for this study was designed to mirror the pediatric screening guidelines for NAFLD.(18) Therefore children had to be at least 10 years old and either overweight or obese. In the clinical notes from the primary care office there had to be documentation of screening for NAFLD with ALT and referral to pediatric gastroenterology for evaluation of “elevated ALT” or “suspected NAFLD” or “NAFLD”. There was not a study inclusion threshold set for ALT; rather the determination that the screening ALT was abnormal was made by the primary care provider. The parent(s) of all subjects provided written informed consent. Written assent was obtained for all children. The protocol was approved by the institutional review boards of the University of California, San Diego and Rady Children’s Hospital San Diego.

## Standard of Care Clinical Evaluation of Suspected NAFLD

The clinical evaluation of the children was at the discretion of the attending pediatric gastroenterologist and not dictated by research protocol. Information generated in the clinical evaluation of suspected NAFLD was captured prospectively. To provide clinical context for the study, details of this diagnostic process are provided.

**Pediatric Gastroenterology Clinic**—All children underwent a comprehensive history and physical as part of the clinical consultation for suspected NAFLD. The history included investigation of potential hepatotoxic medication intake as well as age-appropriate interviewing for relevant lifestyle factors including unprotected sexual activity, alcohol, tobacco, and recreational drug use. Height and weight were measured. Physical examination also included assessment for signs of chronic liver disease.(22–24) Initial laboratory studies performed in all children at least 1 month after screening labs included hepatic panel (ALT, AST, alkaline phosphatase, total protein, albumin, total bilirubin, direct bilirubin) and gamma glutamyl transferase (GGT) to assess the chronicity and nature of aminotransferase elevation; complete blood count to assess for anemia and evidence of splenic sequestration related to portal hypertension; and coagulation studies to assess hepatic synthetic function. If this confirmatory testing showed continued evidence for liver disease, additional laboratory studies were performed as ordered by the pediatric gastroenterologist based upon the clinical context. These labs included evaluation of both hepatic etiologies (hepatitis A IgM, hepatitis B surface antigen, hepatitis B surface antibody, hepatitis C antibody, HIV ELISA, alpha-1 antitrypsin phenotype, anti-nuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-liver kidney microsomal antibody, quantitative IgG, ceruloplasmin, 24-hour urinary copper measurement) and extra-hepatic etiologies (tissue transglutaminase IgA, quantitative IgA, serum amino acids, urine organic acids, serum acylcarnitine, profile, creatine kinase, erythrocyte sedimentation rate, C-reactive protein, thyroid stimulating hormone, and free thyroxine). In children who had no symptoms or signs of liver disease by history or physical examination, and all laboratory results were normal on confirmatory testing, further evaluation was not pursued given low likelihood of liver disease. When there was evidence for chronic liver disease based upon history, physical and/or laboratory testing, a percutaneous liver biopsy was offered for diagnosis.(25)

**Liver Biopsy**—Children who underwent clinical liver biopsy did so according to the standard clinical protocol in use at our institution. Anesthesia was provided by an attending pediatric anesthesiologist. Children underwent a mask induction using a combination of gas ventilation with oxygen, nitrous oxide, and sevoflurane. An intravenous line was placed and supplemental propofol and fentanyl was given according to the anesthesiologist's discretion. Hemodynamic monitoring was placed. Most patients were mask ventilated or had laryngeal mask airways placed. Ventilation was spontaneous. A time out was performed to confirm the correct patient and procedure. Children were positioned supine, with the right hand raised. Limited ultrasonography of the liver was performed to identify the ideal biopsy path. Liver biopsy was performed by an experienced pediatric gastroenterologist using a 15-gauge Jamshidi needle. A portion of tissue was placed in saline and brought fresh to pathology and a portion was placed in formalin for standard processing. After the procedure was completed, patients were taken to the post anesthesia care unit (PACU), monitored and observed for 4 hours prior to discharge.

**Pathology**—Pathology procedures were performed according to standard clinical protocol within our institution. Formalin-fixed paraffin-embedded liver sections were stained with hematoxylin and eosin, periodic acid Schiff with and without diastase, Masson trichrome, reticulin, and iron histochemical stains. Fresh frozen sections were stained with oil-red-O. Slides were evaluated systematically (adequacy, overall architecture, portal tracts, and

parenchyma) by an experienced, board-certified, pediatric pathologist. Additional stains were performed and reviewed as needed based upon the clinical context. Fibrosis was staged using standard methods relevant to the specific pathologic findings (e.g. Kleiner for NAFLD, METAVIR for viral hepatitis, etc.) (26, 27) The pathological diagnosis was recorded.

**Diagnosis**—The final diagnosis was made by the pediatric gastroenterologist incorporating all available information from clinical interview, medical record, physical examination, laboratory testing, and review of histopathology. A diagnosis of NAFLD was based on exclusion of other causes of steatosis by clinical history, laboratory studies, and histology in addition to histologic demonstration of  $\geq 5\%$  of hepatocytes containing macrovesicular fat. Following the prevailing standard, for those biopsies indicative of NAFLD, the diagnosis of steatohepatitis was based upon the pathologists' interpretation of the global histological features including steatosis, lobular and portal inflammation, and ballooning degeneration of hepatocytes.(26) The diagnoses of other liver diseases were made based upon relevant society guidelines and standard gastroenterology, hepatology, and pathology reference text books.(24, 28, 29) For example the diagnosis of autoimmune hepatitis was made following the recommendations of the AASLD Practice Guideline on the Diagnosis and Management of Autoimmune Hepatitis. (30)

### Data Collection

Information generated in the clinical evaluation of suspected NAFLD was captured prospectively. Age and sex were recorded. Because race and ethnicity influence the risk for NAFLD, each child's race and ethnicity were self-identified by the parent(s). Height and weight were recorded. From the primary care provider's office records, the screening ALT and AST values were recorded. In addition, from the pediatric gastroenterology clinical record, we prospectively recorded the values for laboratory assays performed for the evaluation of liver disease. Adverse events were recorded as problems in the operating room, patient complaints in the PACU, return to the hospital, calls to gastroenterology, and by report at outpatient follow-up visit.

### Data Analysis

**Calculated variables**—Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. BMI percentiles were determined from the Centers for Disease Control and Prevention 2000 growth curves. BMI z scores (SDs from the national reference mean for a given age and gender of children's BMI values) also were determined.

**Definitions**—Subjects were classified as overweight (BMI 85th to 94th percentiles) or obese (BMI  $\geq 95$ th percentile). The most common value used at children's hospitals in the United States for the upper limit of normal for ALT is 40 U/L. (31) Therefore two times the ULN was defined as 80 U/L. This value was used to assess the diagnostic performance of the pediatric guideline recommendation to use two times the ULN for ALT as the threshold for further evaluation. As a comparison, we also evaluated recently proposed biology-based thresholds for the ULN in children derived from the SAFETY study.(31) These are gender-specific with ULN of 25 U/L in boys and 22 U/L in girls. Therefore two times the biology-based ULN was defined as 50 U/L for boys and 44 U/L for girls. Advanced fibrosis was defined as bridging fibrosis or cirrhosis.

**Statistics**—Data were expressed as mean  $\pm$  standard deviation (if not normally distributed then geometric means were reported) or frequency and percentage. Continuous variables were analyzed with Student's t test; the Mann-Whitney U test was used for nonparametric measures. The Pearson Chi-Square test was used to test for differences in proportions. All

hypothesis tests were 2-tailed. Significance was defined *a priori* at  $\alpha$  value of 0.05. Analyses were performed with Statistica 10 (StatSoft, Inc., Tulsa, OK).

We performed a post-hoc analysis of published indices for NAFLD and advanced fibrosis using readily available clinical data points.(32) For the detection of NAFLD we tested the Fatty Liver Index (FLI).(33) The FLI was calculated as  $(e^{0.953 \cdot \log_e(\text{triglycerides})} + 0.139 \cdot \text{BMI} + 0.718 \cdot \log_e(\text{GGT}) + 0.053 \cdot \text{waist circumference} - 15.745) / (1 + e^{0.953 \cdot \log_e(\text{triglycerides})} + 0.139 \cdot \text{BMI} + 0.718 \cdot \log_e(\text{GGT}) + 0.053 \cdot \text{waist circumference} - 15.745) \cdot 100$ . The index produces a score from 1 to 100. Scores of < 30 are considered negative for NAFLD, scores between 31 and 59 are considered indeterminate, and scores > 60 are considered positive for NAFLD. For the detection of advanced fibrosis we tested the FIB-4 index.(34, 35) This was calculated as  $(\text{Age} \times \text{AST}) / (\text{Platelets} \times (\text{sqr}(\text{ALT})))$ . Values < 1.3 are considered negative, values between 1.3 and 2.67 are considered indeterminate, and values > 2.67 are considered as positive for advanced fibrosis. Finally, we tested the Pediatric NAFLD Fibrosis Index (PNFI).(36) A linear predictor for PNFI was calculated as linear predictor ( $lp$ ) =  $-6.539 \times \log_e[\text{age (years)}] + 0.207 \times \text{waist (cm)} + 1.957 \times \log_e[\text{triglycerides (mg/dl)}] - 10.074$ . This linear predictor is transformed into a PNFI score:  $(1 / (1 + e^{-lp})) \times 10$ . PNFI scores  $\geq 9$  are considered positive for fibrosis. We tested for differences in the PNFI score between those children with and without advanced fibrosis.

## RESULTS

### Aim 1: Demographics and Clinical Features

Children were screened and referred by 58 primary care providers including 42 pediatricians, 9 family physicians, and 7 pediatric nurse practitioners. A study flow chart is shown in Figure 1. We enrolled 347 children who met eligibility criteria (were  $\geq 10$  years old, overweight or obese, identified by primary care screening as having elevated ALT and referred to pediatric gastroenterology for suspected NAFLD). As shown in Table 2, the majority of children were boys (223/347, 64%). The mean age was 13.5 years. The majority of children were obese (93%), with the remaining children being overweight (7%). The mean screening ALT of children with suspected NAFLD was 99 U/L. The screening ALT was  $\geq 40$  U/L in 90% (313/347) of children referred. The screening ALT was higher than the gender-specific biological ULN for all children referred for suspected NAFLD.

Following clinical evaluation by a pediatric gastroenterologist, 21% (74/347) of children identified by screening as having suspected NAFLD were determined not to have liver disease based upon the absence of symptoms or signs of liver disease by history or physical examination, and normal laboratory results on confirmatory testing. The remaining 273 children were offered clinical liver biopsy. Liver biopsy was not performed in 6% of these children due to either parental refusal ( $n = 4$ ) or insurance denial ( $n = 14$ ). Notably, children whose parents refused liver biopsy were significantly ( $p < 0.05$ ) younger (11 years-old) than the group overall (13 years-old). Moreover, children who had liver biopsy denied by insurance were significantly ( $p < 0.05$ ) more likely to be Hispanic (92%) than the group overall (70%). The remaining 255 children successfully underwent liver biopsy. No child experienced bleeding or required post-procedure hospitalization. While in the recovery room 3% of patients reported symptoms that were successfully resolved prior to discharge (5 complained of pain and 2 of nausea). After discharge to home, 1 patient's parent called about their child's pain which was successfully addressed by telephone. All children were seen for clinical follow-up and review of biopsy results at a mean follow-up interval of 18 days (range 4 – 97). At follow-up an additional 9 children (3%) reported that they had experienced some degree of minor discomfort after discharge post liver-biopsy. No child was brought to urgent care nor required readmission.

## Aim 2: Diagnosis of NAFLD

The combination of histology, clinical and laboratory features yielded a diagnosis of NAFLD in 55% of those children identified by screening and referral (193/347) and in 75% of those who underwent liver biopsy (193/255). Liver histology was normal in 3 children (1%). Liver disease other than NAFLD was present in 18% of those referred (61/347) and 24% of those biopsied (61/255). Notably there were 2 children who had both NAFLD and autoimmune hepatitis. As shown in Figure 2, boys had significantly ( $p < 0.01$ ) higher ALT than girls. Amongst subgroups this was true both for children without liver disease and for children with NAFLD. However, ALT did not differ between boys and girls with liver disease other than NAFLD.

For children with liver disease other than NAFLD, autoimmune hepatitis was the most common diagnosis ( $n=11$ ). Other forms of hepatitis included: drug-induced ( $n=6$ ), eosinophilic ( $n=4$ ), granulomatous ( $n=1$ ), idiopathic ( $n=8$ ), viral (hepatitis B, hepatitis C, each  $n=2$ ), secondary to alcohol abuse ( $n=2$ ), associated with herbal supplement ( $n=1$ ), and associated with asymptomatic colitis ( $n=1$ ). Drug-induced hepatitis was associated with medications including aripiprazole, cetirizin, isotretinoin, minocycline and valproic acid. Microvesicular steatosis was present in 20 children and was idiopathic in 10. Specific causes identified for microvesicular steatosis included celiac disease ( $n=4$ ), drug-induced ( $n=5$ ), and muscle disease ( $n=1$ ). Additional diagnoses included alpha-1-antitrypsin deficiency ( $n=1$ ), sclerosing cholangitis ( $n=1$ ), and congestive hepatopathy ( $n=1$ ). As shown in Table 1, children with liver disease other than NAFLD were significantly older, more likely to be female, and had lower ALT at both screening and confirmation. Positive ANA was significantly more frequent in children with liver disease other than NAFLD (36%) than children with NAFLD (19%).

## Aim 3: Diagnosis of NASH

NASH was diagnosed in 105 children who represent 30% of children who were identified by screening and referred to pediatric gastroenterology, 41% of children who underwent liver biopsy, and 54% of those children with NAFLD. Children with NASH had significantly ( $p < 0.001$ ) higher mean ALT at screening ( $100 \pm 107$  versus  $79 \pm 79$  U/L) and at confirmation ( $94 \pm 89$  versus  $71 \pm 74$  U/L) than children who did not have NASH. However, there was no significant difference in mean values of GGT, ceruloplasmin or frequency of positive ANA or ASMA between children with and without NASH.

## Aim 4: Diagnosis of Advanced Fibrosis

Advanced fibrosis was present in 11% (38/347) of all children in the study population. The rate of advanced fibrosis was greater in children with NAFLD (17%, 33/193) than in children with liver disease other than NAFLD (8%, 5/62). Advanced fibrosis was seen in autoimmune hepatitis ( $n=3$ ), sclerosing cholangitis ( $n=1$ ), and idiopathic hepatitis ( $n=1$ ). As a group, children with advanced fibrosis did not significantly differ by age, sex, or severity of obesity. Children with advanced fibrosis did have significantly ( $p < 0.01$ ) higher ALT ( $120 \pm 140$  U/L) and AST ( $79 \pm 87$  U/L) than children without advanced fibrosis (ALT  $82 \pm 78$  U/L, AST  $57 \pm 45$  U/L). Children with advanced fibrosis also had significantly ( $p < 0.001$ ) higher GGT ( $58 \pm 90$ ) than children without advanced fibrosis ( $35 \pm 41$ ). Ceruloplasmin was also significantly ( $p < 0.05$ ) higher in children with advanced fibrosis ( $38 \pm 10$ ) than children without advanced fibrosis ( $33 \pm 8$ ).

## Aim 5: Evaluation of ALT in the Diagnostic Process

Table 3 shows the study population separated into those with screening ALT above and below two times the clinical upper limit of normal. As expected children with screening

ALT  $\geq 80$  had significantly higher ALT and AST than children with screening ALT  $< 80$ , but were otherwise not significantly different with regard to age, sex, race, ethnicity, height, weight, or BMI. For children with screening ALT  $\geq 80$ , NAFLD was diagnosed in 71% and liver disease other than NAFLD was present in 14%. For children with screening ALT that was elevated but  $< 80$ , NAFLD was diagnosed in 43% and liver disease other than NAFLD in 22%. NASH was significantly ( $p < 0.01$ ) more common in children with screening ALT  $\geq 80$  (41%, 64/155) than in children with screening ALT  $< 80$  (21%, 41/192). Similarly, advanced fibrosis was significantly ( $p < 0.01$ ) more common in children with screening ALT  $\geq 80$  (19%, 29/155) than in children with screening ALT  $< 80$  (6%, 9/192). For the diagnosis of NAFLD in overweight and obese children  $\geq 10$  years of age, screening ALT of  $\geq 80$  had a sensitivity of 57% and a specificity of 71%. For the diagnosis of NASH, screening ALT  $\geq 80$  had a sensitivity of 61% and a specificity of 62%. For advanced fibrosis, screening ALT  $\geq 80$  had a sensitivity of 76% and a specificity of 59%.

As a comparison, we also analyzed the diagnostic accuracy of using two times the gender-specific, biology-based, ALT thresholds. For the diagnosis of NAFLD in overweight and obese children  $\geq 10$  years of age, ALT  $\geq 50$  for boys and  $\geq 44$  for girls had a sensitivity of 88% and a specificity of 26%. For the diagnosis of NASH, two times the gender-specific biology-based thresholds had a sensitivity of 90% and a specificity of 22%. For advanced fibrosis, screening ALT  $\geq 50$  for boys and  $\geq 44$  for girls had a sensitivity of 92% and a specificity of 19%.

### Predictive Indices

There were 270 children with FLI  $< 30$ , of whom 163 (60%) had NAFLD. There were 75 children with indeterminate values (30–59) of whom 29 (39%) had NAFLD. There were only 2 children who had a score  $> 60$ ; 1 with NAFLD and 1 without NAFLD. Because FLI only detected 1 out of 193 children with NAFLD further diagnostic analysis was not done. The mean FIB-4 score among children with advanced fibrosis was 0.34. None of the 38 children with advanced fibrosis had a positive FIB-4 score. For PNFI, there was no significant ( $p = 0.92$ ) difference between children with advanced fibrosis (mean = 6) and children without advanced fibrosis (mean = 6).

## DISCUSSION

We studied a large clinical sample of overweight and obese children who were identified as having suspected NAFLD by screening in primary care following pediatric guidelines and referred to pediatric gastroenterology. Children were evaluated by a pediatric gastroenterologist and those with evidence of chronic liver disease underwent liver biopsy which was well-tolerated. NAFLD was the most common diagnosis established. However, many children with suspected NAFLD were shown to have liver disease other than NAFLD. Amongst children with NAFLD, approximately half had steatohepatitis. Furthermore, many overweight and obese children were determined to have previously unrecognized advanced fibrosis.

Society recommendations to screen overweight and obese children for NAFLD were based in part on the asymptomatic nature of chronic liver disease that evades diagnosis without a screening effort. The pediatric guidelines as applied by primary care providers identified many children with liver disease, most commonly NAFLD. In addition, the current data demonstrated that not all overweight and obese children with a positive screening ALT will have liver disease. Thus one major challenge is the interpretation of ALT values. As shown in the SAFETY study, there is wide institution to institution variability in the definition of the normal range for ALT and controversy over whether or not to use multipliers of the upper limit of normal. (31) This creates confusion for pediatricians, gastroenterologists, and



endocrinologists as well as for the children themselves and their families. The current data show the strengths and limitations of various thresholds for ALT in children. The pediatric guidelines suggest using 2 times the ULN as the criterion for referral to pediatric gastroenterology. However our data suggest that primary care providers vary greatly in their choice of threshold used for referral. Although the use of 2 times the ULN would improve the specificity for NAFLD, many children with NAFLD would be missed including some with NASH and advanced fibrosis. In addition, contrary to conventional wisdom, children with liver disease other than NAFLD had lower ALT than children with NAFLD. Thus national standardization of ALT thresholds is needed, but no single ALT threshold will be sufficient to be considered diagnostic.

Once the possibility of liver disease has been detected by screening, it is important to make an accurate diagnosis. One important lesson from this study is that physicians should not tell children that they have fatty liver based solely upon the finding of elevated ALT in the context of obesity. Determining whether a child has NAFLD or another form of liver disease, has important therapeutic implications, as many of the possible etiologies have specific therapies. Although it is true that some diseases, such as hepatitis C, can be detected by serologic testing, many other diseases, such as autoimmune hepatitis, require liver biopsy to distinguish from NAFLD. In fact, the screening test for autoimmune hepatitis, auto-antibodies, has been reported to be positive in approximately 20% of patients with NAFLD. (37) Indeed, in this study, a positive ANA did not sufficiently distinguish between those with NAFLD or autoimmune hepatitis. Because there are no alternative tests with satisfactory diagnostic accuracy, liver biopsy remains the clinical standard to determine the etiology and stage of liver disease. Liver biopsy is not without risk; however, the current data show that when performed by experienced personnel, it can be done with minimal adverse events.

The rationale for detecting NAFLD, and especially NASH, is based in part upon the risk for progression to cirrhosis. In a national multi-center study, advanced fibrosis was reported at the time of diagnostic liver biopsy in nearly 1 of 7 children with NAFLD.(38) Our study had similar findings, with 17% of children with NAFLD having advanced fibrosis. The detection of advanced fibrosis is important because these are the children who in the short term are at risk for portal hypertension and its consequences, and in the long term may require liver transplant and/or develop hepatocellular carcinoma.(39) Beyond the hepatic consequences, obese children with NAFLD are phenotypically distinct from obese children without NAFLD. NAFLD is an independent risk factor for diabetes and cardiovascular disease.(40) In addition, children with NAFLD also have substantially lower bone mineralization than age and adiposity matched peers.(41) Thus, the early identification of NAFLD has the potential to be clinically important.

The current study is notable for its large sample size of overweight and obese children identified by screening in primary care as having suspected NAFLD based upon prevailing national clinical guidelines and referred to pediatric gastroenterology. In addition, data were available for detailed diagnostic outcomes based upon history, physical examination, laboratory evaluation, liver biopsy and histology. These data represent children identified by screening and not those tested based upon symptoms, thus may not reflect all overweight or obese children with elevated liver chemistry. Moreover, given the influence of race and ethnicity, there are likely to be differences in findings depending upon the demographics of the community being considered.

## CONCLUSION

In conclusion, screening of overweight and obese children in primary care for NAFLD with referral to pediatric gastroenterology has the potential to identify clinically relevant liver pathology. NAFLD was the most common explanation for elevated ALT in children detected by screening, but almost as common was either the absence of liver disease or an alternate form of chronic liver disease. The magnitude of ALT elevation was associated with worse disease in group aggregate, but was not an effective discriminate tool on the individual patient level. Importantly, the screening and referral process followed by liver biopsy was able to identify many obese children with advanced fibrosis that would have otherwise remained undiagnosed. Proper treatment of these children rests upon an accurate and definitive diagnosis. Important next steps will include the assessment of the cost and benefits of screening. These can be evaluated at multiple different decision points including initial screening for liver disease, referral for further evaluation of liver disease, and the decision to perform liver biopsy for definitive diagnosis and disease staging. The current data can be used for efforts to develop a consensus on how to value these risk and rewards. In turn, with larger observational data, clinical practice guidelines can be refined to best identify overweight children with liver disease in the most appropriate manner.

## Acknowledgments

This study was supported in part by UL1RR031980 from the NCCR for the Clinical and Translational Research Institute at UCSD, DK088925-02S1 and NSF GRANT #414916. The funders did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the National Science Foundation.

## Abbreviations

<b>ALT</b>	alanine aminotransferase
<b>ANA</b>	antinuclear antibody
<b>ASMA</b>	anti-smooth muscle antibody
<b>AST</b>	aspartate aminotransferase
<b>BMI</b>	body mass index
<b>GGT</b>	Gamma-glutamyltransferase
<b>HRSA</b>	Health Resources and Services Administration
<b>NAFLD</b>	nonalcoholic fatty liver disease
<b>ULN</b>	upper limit of normal


## References

1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics*. 2006; 118(4):1388–93. [PubMed: 17015527]
2. Lindback SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, et al. Pediatric nonalcoholic fatty liver disease: a comprehensive review. *Advances in pediatrics*. 2010; 57(1):85–140. [PubMed: 21056736]
3. Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. *Seminars in pediatric surgery*. 2009; 18(3): 144–51. [PubMed: 19573756]


4. Rubinstein E, Lavine JE, Schwimmer JB. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. *Seminars in liver disease*. 2008; 28(4):380–5. [PubMed: 18956294]
5. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. *Hepatology*. 2005; 42(3):641–9. [PubMed: 16116629]
6. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. *The American journal of gastroenterology*. 2002; 97(9):2460–2. [PubMed: 12358273]
7. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology*. 2003; 37(5):1202–19. [PubMed: 12717402]
8. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. *Int J Obes Relat Metab Disord*. 2000; 24(6):772–6. [PubMed: 10878685]
9. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. *The Journal of pediatrics*. 2000; 136(6):727–33. [PubMed: 10839867]
10. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr*. 2000; 30(1):48–53. [PubMed: 10630439]
11. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. *The Journal of pediatrics*. 2003; 143(4):500–5. [PubMed: 14571229]
12. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. *Pediatrics*. 2005; 115(5):e561–5. [PubMed: 15867021]
13. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. *The Journal of pediatrics*. 2013; 162(3):496–500. e1. [PubMed: 23084707]
14. Riley MR, Bass NM, Rosenthal P, Merriman RB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. *The Journal of pediatrics*. 2005; 147(6):839–42. [PubMed: 16356443]
15. Barlow SE, Expert C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics*. 2007; 120 (Suppl 4):S164–92. [PubMed: 18055651]
16. August GP, Caprio S, Fennoy I, Freemark M, Kaufman FR, Lustig RH, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. *The Journal of clinical endocrinology and metabolism*. 2008; 93(12):4576–99. [PubMed: 18782869]
17. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. *Journal of pediatric gastroenterology and nutrition*. 2012; 54(5):700–13. [PubMed: 22395188]
18. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. *Pediatrics*. 2007; 120 (Suppl 4):S193–228. [PubMed: 18055652]
19. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology*. 2012; 142(7):1592–609. [PubMed: 22656328]
20. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012; 55(6):2005–23. [PubMed: 22488764]

21. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *The American journal of gastroenterology*. 2012; 107(6):811–26. [PubMed: 22641309]
22. D'Agata ID, Balistreri WF. Evaluation of liver disease in the pediatric patient. *Pediatrics in review/ American Academy of Pediatrics*. 1999; 20(11):376–90. quiz 89–90. [PubMed: 10551891]
23. Tsouka A, McLin VA. Complications of chronic liver disease. *Clinics and research in hepatology and gastroenterology*. 2012; 36(3):262–7. [PubMed: 22521556]
24. Suchy, FJ.; Sokol, RJ.; Balistreri, WF., editors. *Liver Disease in Children*. 3. Cambridge University Press; 2007.
25. Ovchinsky N, Moreira RK, Lefkowitz JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. *Advances in anatomic pathology*. 2012; 19(4):250–62. [PubMed: 22692288]
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005; 41(6):1313–21. [PubMed: 15915461]
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet*. 1997; 349(9055):825–32. [PubMed: 9121257]
28. Kleinman, R.; Goulet, O.; Mieli-Vergani, G.; Sanderson, I.; Sherman, P.; Shneider, B., editors. *Walker's Pediatric Gastrointestinal Disease*. 5. People's Medical Publishing House; 2008.
29. Burt, AD.; Portmann, BC.; Ferrell, LD., editors. *MacSween's Pathology of the Liver*. 6. 2011. MacSween's Pathology of the Liver.
30. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. *Hepatology*. 2010; 51(6):2193–213. [PubMed: 20513004]
31. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. *Gastroenterology*. 2010; 138(4):1357–64. 64 e1–2. [PubMed: 20064512]
32. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Alimentary pharmacology & therapeutics*. 2011; 33(5):525–40. [PubMed: 21198708]
33. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC gastroenterology*. 2006; 6:33. [PubMed: 17081293]
34. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006; 43(6):1317–25. [PubMed: 16729309]
35. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2009; 7(10):1104–12. [PubMed: 19523535]
36. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. *BMC medicine*. 2009; 7:21. [PubMed: 19409076]
37. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. *Gastroenterology*. 2008; 135(6):1961–71. e2. [PubMed: 19013463]
38. Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB. Symptoms and quality of life in obese children and adolescents with nonalcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2009; 31:396–406. [PubMed: 19863497]
39. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut*. 2009; 58(11):1538–44. [PubMed: 19625277]

40. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. *Circulation*. 2008; 118(3):277–83. [PubMed: 18591439]
41. Pardee PE, Dunn W, Schwimmer JB. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. *Alimentary pharmacology & therapeutics*. 2012; 35(2):248–54. [PubMed: 22111971]



**Figure 1.** Flowchart shows study the application of inclusion and exclusion criteria along with progression to final diagnosis. In the terminal nodes for diagnosis, the cumulative number is greater than the number biopsied because 2 children had dual diagnosis.



**Figure 2.**

Box and whiskers plot for screening ALT separated by final diagnosis: no liver disease, NAFLD, or liver disease other than NAFLD. Within each diagnostic category, data are shown separately for boys (○) and girls (□). The horizontal lines inside the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the minimum and maximum values. The Y axis was truncated at 450 U/L. Only the group of boys with NAFLD included outliers with screening ALT above 450 U/L.

**Table 1**

Society Guidelines regarding Screening Overweight and Obese Children for NAFLD

Society	Recommend screening children for NAFLD			
	Yes	No	Uncertain	Not Stated
American Academy of Family Physicians	X			
American Academy of Pediatrics	X			
American Association for the Study of Liver Disease			X	
American College of Gastroenterology			X	
American Gastroenterological Association			X	
Endocrine Society	X			
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition	X			
National Association of Pediatric Nurse Practitioners	X			
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition				X



**Table 2**

## Characteristics of Study Population by Diagnosis

Variables	Children Identified by Screening N = 347	Children with Liver Diagnosis	
		NAFLD N = 193	Other Liver Disease N = 61
Age, mean (SD) **	13.5 (2.2)	13.6 (2.2)	14.5 (2.4)
Sex, N (%) **			
Boys	223 (64)	140 (72)	29 (48)
Girls	124 (36)	53 (28)	32 (52)
Race and ethnicity, N (%)			
Asian, non-Hispanic	16 (5)	8 (4)	6 (10)
Hispanic	252 (72)	147 (76)	38 (62)
White, non-Hispanic	45 (13)	21 (10)	12 (20)
Other, non-Hispanic	34 (10)	17 (8)	5 (8)
Weight, mean (SD), Kg	80.1 (20.7)	81.5 (22.6)	80.8 (17.3)
Height, mean (SD), cm	157 (15.6)	157(15.0)	159 (12.6)
Body Mass Index (Kg/m <sup>2</sup> )			
mean (SD)	31.5 (6.0)	31.5 (4.8)	31.4 (4.4)
percentile, mean (SD)	98.1 (1.6)	98.4 (1.5)	97.4 (1.9)
Z-Score, mean (SD)	2.2 (0.36)	2.2 (0.33)	2.0 (0.34)
ALT, mean (SD), U/L			
Screening*	99 (89)	98 (95)	86 (74)
Confirmation **	80 (68)	89 (75)	75 (57)
AST, mean (SD), U/L			
Screening	67 (50)	63 (55)	68 (57)
Confirmation	57 (39)	60 (43)	56 (30)

Statistical tests are for NAFLD versus other liver disease.

\*  
p< 0.05,

\*\*  
p< 0.001

**Table 3**

Comparison of Children with ALT Above or Below 2 Times Upper Limit of Normal

Variables	Screening ALT < 80 (N=192)	Screening ALT ≥ 80 (N=155)
Age, mean (SD)	13.5 (2.2)	13.6 (2.2)
Sex, N (%)		
Boys	111 (58)	112 (72)
Girls	81 (42)	43 (28)
Race and ethnicity, N (%)		
Asian, non-Hispanic	9 (4)	7 (4)
Hispanic	133 (69)	119 (76)
White, non-Hispanic	31 (16)	14 (9)
Other, non-Hispanic	19 (10)	15 (10)
Weight, mean (SD), Kg *	77.8 (19.9)	83 (21.4)
Height, mean (SD), cm	157 (12.2)	158 (19.1)
Body Mass Index (Kg/m <sup>2</sup> )		
mean (SD)	31.3 (6.9)	31.8 (4.5)
Z-Score, mean (SD)	2.1 (0.3)	2.2 (0.3)
ALT, mean (SD), U/L		
Screening **	54 (14)	156 (95)
Confirmation	59 (43)	107 (83)
AST, mean (SD), U/L		
Screening	46 (20)	93 (63)
Confirmation *	45 (22)	71 (49)
Diagnosis		
NAFLD, N (%)	83 (43)	110 (71)
Other Liver Disease, N (%)	42 (22)	21 (14)

\* p&lt; 0.05,

\*\* p&lt; 0.001